Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00229658 · ClinicalTrials.gov registry record

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

A clinical trial of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by AstraZeneca.

Completed
Registry status
1,297
Enrollment target
20
Study locations

NCT00229658 is a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 1,297 participants, below the 2,738-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00229658, a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
1,297 participants
Enrollment target
20
Study locations

Study Summary

This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.

Conditions Studied

Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus

Interventions

  • DRUG pramlintide acetate

Study Locations (20)

California

  • Research Site - Anaheim
  • Research Site - Encinitas
  • Research Site - Escondido
  • Research Site - Fresno
  • Research Site - Lafayette
  • Research Site - Moreno Valley
  • Research Site - Sacramento
  • Research Site - Salinas
  • Research Site - Santa Barbara
  • Research Site - Torrance
  • Research Site - Vacaville

Alabama

  • Research Site - Birmingham
  • Research Site - Montgomery

Colorado

  • Research Site - Arvada
  • Research Site - Aurora

Florida

  • Research Site - Hialeah
  • Research Site - Jacksonville

Arizona

  • Research Site - Tucson

Connecticut

  • Research Site - Norwalk

Delaware

  • Research Site - Wilmington

Trial Details

FieldValue
Enrollment Target 1,297 participants
Start Date 2005-09
Est. Completion 2008-05

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00229658

The ClinicalTrials.gov registry entry for NCT00229658 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,297 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,738-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (53% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which pramlintide acetate is the first listed.

NCT00229658 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT00229658 about?

NCT00229658 is a clinical study titled "An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes". This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescrib...

What is the current status of trial NCT00229658?

This trial is currently completed. The enrollment target is 1,297 participants. The study started on 2005-09. Estimated completion is 2008-05.

What conditions does trial NCT00229658 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT00229658?

The interventions under investigation include: pramlintide acetate (DRUG).

Who is sponsoring clinical trial NCT00229658?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00229658 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

Type 1 Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.